received an overall rating of 6 out of 10 stars from 3 reviews. See also Warning section. Williams LH, Fleckman P "Painless periungual pyogenic granulomata associated with reverse transcriptase inhibitor therapy in a patient with human immunodeficiency virus infection." 2. Sims KA, Woodland AM "Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection." Mylan Pharmaceuticals Inc, Morgantown, WV. Brinkman K, terHofstede HJM, Burger DM, Smeitinkt JAM, Koopmans PP "Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway." Available for Android and iOS devices.We comply with the HONcode standard for trustworthy health information - Although not all of these side effects may occur, if they do occur they may need medical attention.Check with your doctor immediately if any of the following side effects occur:Get emergency help immediately if any of the following symptoms of overdose occur:Some side effects may occur that usually do not need medical attention. Cerner Multum, Inc. "UK Summary of Product Characteristics." The following list contains some of the key side effects that may occur while taking lamivudine. Additionally, patients with Hepatocellular injury described as AST/ALT elevation has been reported in association with loxapine administration; rarely, jaundice and/or hepatitis has been reported as possibly related to treatment.1. If you notice any other effects, check with your healthcare professional.Call your doctor for medical advice about side effects. CNS Effects: Manifestations of adverse effects on the central nervous system, other than extrapyramidal effects, have been seen infrequently.Drowsiness, usually mild, may occur at the beginning of therapy or when dosage is increased. If you notice any other effects, check with your healthcare professional. Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate) is a three-drug combination of a non-nucleoside reverse transcriptase inhibitor [NNRTI]), and two nucleoside analogue reverse transcriptase inhibitors indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no antiretroviral treatment history. Difficulty with speaking or swallowing 2. lip smacking or puckering 3. loss of balance control 4. mask-like face 5. puffing of the cheeks 6. rapid or fine, worm-like movements of the tongue 7. restlessness or desire to keep moving 8. shuffling walk 9. slowed movements 10. stiffness of the arms and legs 11. trembling and shaking of the fingers and hands 12. uncontrolled chewing movements 13. uncontrolled movements of the arms or legs This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.Things to remember when you fill your prescription.WebMD does not provide medical advice, diagnosis or treatment. The causal relationship to stopping therapy was unknown.Rash, pruritus, and alopecia have also been reported during postmarketing experience.Decreased absolute neutrophil count (less than 750/mm3), platelets (less than 50,000/mm3), and hemoglobin (less than 8 g/dL) have been reported in up to 15%, up to 4%, and up to 2.9% of patients, respectively.Elevated CPK (at least 7 x baseline) has been reported in 9% of patients.Elevated CPK, rhabdomyolysis, and muscle disorders (including myalgia and cramps) have also been reported during postmarketing experience.-Frequency not reported: Redistribution/accumulation of body fat (including central Lactic acidosis and severe hepatomegaly with steatosis (including fatal cases) have been reported with the use of nucleoside analogs.Redistribution/accumulation of body fat has been reported with antiretroviral therapy; causality has not been established.1. O 04. Office of AIDS Research Advisory Council (OARAC). Glaxo Wellcome, Research Triangle Park, NC. Available from: URL: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf." It is not known if these were related to loxapine administration.Use of the inhaler was shown to cause bronchospasm in clinical pulmonary safety trials as measured by FEV1 and respiratory signs and symptoms. Asari A, Iles-Smith H, Chen YC, et al. Med Lett Drugs Ther 43 (2001): 103-816. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:Other side effects not listed may also occur in some patients.